|
13 Dec 2007 |
Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
|
|
12 Dec 2007 |
Final phase 3 study confirms very favourable effect of liraglutide on blood glucose control and body weight
|
|
11 Dec 2007 |
ZymoGenetics Presents PEG-Interferon Lambda Phase 1a Data
|
|
11 Dec 2007 |
Medicis and Revance Announce Strategic Collaboration
|
|
10 Dec 2007 |
ZymoGenetics Presents Positive Interim Phase 1 Results for IL-21 in Combination with Rituxan(R) in B Cell Lymphoma
|
|
10 Dec 2007 |
CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
|
|
10 Dec 2007 |
Gloucester Pharmaceuticals Reports Clinically Significant Responses in Pivotal Trial of Romidepsin for Cutaneous T-cell Lymphoma at the 2007 American Society of Hematology (ASH) Annual Meeting
|
|
09 Dec 2007 |
Nuvelo Phase 3 SONOMA-2 Trial Shows Alfimeprase has the Potential to Restore Catheter Function
|
|
08 Dec 2007 |
Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints
|
|
07 Dec 2007 |
Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
|
|
07 Dec 2007 |
Submission of Marketing Authorisation Application for Dapoxetine in Europe
|
|
07 Dec 2007 |
Access Pharmaceuticals Demonstrates Ability To Significantly Reduce Glucose Levels in Pre-clinical Testing of
|
|
06 Dec 2007 |
Ipsen submits a Biologics License Application (BLA) in cervical dystonia to the FDA for Dysport(R)
|
|
06 Dec 2007 |
Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA
|
|
05 Dec 2007 |
Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
|
|
05 Dec 2007 |
GTC Biotherapeutics Obtains Licenses to Factor IX, Factor VIII and Fibrinogen
|
|
04 Dec 2007 |
ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
|
|
04 Dec 2007 |
Early Treatment with COPAXONE® Demonstrated Robust Protection against Progression to Clinically Definite Multiple Sclerosis in the PreCISe Study
|
|
03 Dec 2007 |
Fibrex Medical Completes Enrolment of Phase II Trial of Treatment for
|
|
03 Dec 2007 |
Clal Biotechnology Industries and Teva Pharmaceuticals Solidify their Collaboration for Final Stage Development of Type 1 Diabetes Drug
|
|
03 Dec 2007 |
BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
|
|
03 Dec 2007 |
Buck Institute and Neurobiological Technologies, Inc. Partner to Develop Treatment for Huntington's Disease
|
|
30 Nov 2007 |
Amgen Announces Interim Results of Aranesp(R) ''PREPARE'' Study in Breast Cancer Patients
|
|
29 Nov 2007 |
Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
|
|
28 Nov 2007 |
Immutep Announces Positive Interim Results From a Study of Immufact(R) IMP321 in Metastatic Breast Cancer
|
